Gritstone Oncology Inc.

9.10-0.1300-1.41%Vol 472.94K1Y Perf 34.07%
Apr 9th, 2021 16:00 DELAYED
BID9.06 ASK9.10
Open9.08 Previous Close9.23
Pre-Market- After-Market-
 - -  - -%
Target Price
20.50 
Analyst Rating
Strong Buy 1.25
Potential %
125.28 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★     51.45
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Market Cap445.46M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
20.09 
Earnings Date
6th May 2021

Today's Price Range

8.879.22

52W Range

2.5435.20

Summary:

Neutral

Technical Indicators: Buy
Moving Averages: Strong Sell
Performance
1 Week
-10.43%
1 Month
-38.26%
3 Months
71.70%
6 Months
203.33%
1 Year
34.07%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GRTS9.10-0.1300-1.41
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.69-0.690.00
Q03 2020-0.68-0.69-1.47
Q02 2020-0.77-0.6910.39
Q01 2020-0.83-0.7114.46
Q04 2019-0.76-0.77-1.32
Q03 2019-0.68-0.77-13.24
Q02 2019-0.61-0.63-3.28
Q01 2019-0.72-0.6213.89
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.4617.86Positive
6/2021 QR-0.54-8.00Negative
12/2021 FY-2.26-23.50Negative
12/2022 FY-2.15-45.27Negative
Next Report Date6th May 2021
Estimated EPS Next Report-0.46
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume472.94K
Shares Outstanding48.95M
Trades Count5.16K
Dollar Volume6.36M
Avg. Volume3.23M
Avg. Weekly Volume1.51M
Avg. Monthly Volume1.27M
Avg. Quarterly Volume3.37M

Gritstone Oncology Inc. (NASDAQ: GRTS) stock closed at 9.1 per share at the end of the most recent trading day (a -1.41% change compared to the prior day closing price) with a volume of 473.42K shares and market capitalization of 445.46M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 177 people. Gritstone Oncology Inc. CEO is Andrew R. Allen.

The one-year performance of Gritstone Oncology Inc. stock is 34.07%, while year-to-date (YTD) performance is 130.96%. GRTS stock has a five-year performance of %. Its 52-week range is between 2.54 and 35.2, which gives GRTS stock a 52-week price range ratio of 20.09%

Gritstone Oncology Inc. currently has a PE ratio of -3.70, a price-to-book (PB) ratio of 2.77, a price-to-sale (PS) ratio of 177.76, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -49.87%, a ROC of -77.86% and a ROE of -67.29%. The company’s profit margin is -%, its EBITDA margin is -2 821.70%, and its revenue ttm is $2.78 Million , which makes it $0.06 revenue per share.

Of the last four earnings reports from Gritstone Oncology Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.46 for the next earnings report. Gritstone Oncology Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Gritstone Oncology Inc. is Strong Buy (1.25), with a target price of $20.5, which is +125.28% compared to the current price. The earnings rating for Gritstone Oncology Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Gritstone Oncology Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Gritstone Oncology Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 25.80, ATR14 : 1.56, CCI20 : 3.73, Chaikin Money Flow : -0.10, MACD : -0.04, Money Flow Index : 38.73, ROC : 0.99, RSI : 51.38, STOCH (14,3) : 51.52, STOCH RSI : 0.65, UO : 48.54, Williams %R : -48.48), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Gritstone Oncology Inc. in the last 12-months were: Erin Jones (Option Excercise at a value of $3 450), Raphael Rousseau (Option Excercise at a value of $22 800), Raphael Rousseau (Sold 30 000 shares of value $601 269 ), Roman Yelensky (Sold 10 000 shares of value $221 029 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.25
Strong Buy
1.25

Gritstone Oncology Inc.

Gritstone Oncology Inc is a United States based immune-oncology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors including GRANITE-001 and SLATE-001.

CEO: Andrew R. Allen

Telephone: +1 510 871-6100

Address: 5959 Horton Street, Emeryville 94608, CA, US

Number of employees: 177

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

53%47%

Bearish Bullish

48%52%

Bearish Bullish

61%39%

News

Stocktwits